Selective Secretase Targeting for Alzheimer's Disease Therapy

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is characterized by cerebral atrophy and the accumulation of amyloid plaques and neurofibrillary tangles.
• Amyloid plaques are formed by amyloid-beta (Aβ) oligomers, with Aβ42 and Aβ40 being key species.
• The amyloidogenic pathway involves sequential cleavage of amyloid-beta protein precursor (AβPP) by β-secretase (BACE-1) and γ-secretase.

Purpose of the Study:

• To review the latest compounds designed for Alzheimer's disease treatment.
• To summarize structures and activities of novel therapeutic agents targeting Aβ production and neuronal damage.
• To highlight advancements in α-secretase enhancers, β-secretase inhibitors, and γ-secretase modulators.

Main Methods:

• Review of in vitro, in vivo, and clinical trial data for Alzheimer's disease therapeutics.
• Analysis of compound structures and their effects on Aβ production pathways.
• Evaluation of drug properties including solubility, blood-brain barrier penetration, selectivity, and potency.

Main Results:

• Several β-secretase inhibitors (BACE-1) underwent clinical trials but failed to restore cognitive function or reverse disease progression.
• Inhibition of Aβ production alone has not been sufficient for effective Alzheimer's disease treatment.
• Compounds targeting AβPP processing, including α-secretase enhancers and γ-secretase modulators, show promise.

Conclusions:

• Complete inhibition of Aβ production is not an effective therapeutic strategy for Alzheimer's disease.
• Novel strategies focusing on partial Aβ reduction and enhancing neuroprotective pathways are crucial.
• Future therapeutic tools should aim to slow neuronal damage progression, with ongoing research into latest compounds.